What is Cellebrite's revenue?

Written by Editorial Team | Last Updated: August 2026

As of the latest financial reports for the trailing twelve-month (TTM) period in 2026, Cellebrite's revenue is approximately $0.49 billion USD. The company has shown a consistent upward trend in its financial performance over recent years. In 2025, it reported an annual revenue of $0.47 billion, representing an 18.56% increase over its 2024 performance of $0.40 billion. This follows a growth trajectory that saw revenues rise from $0.24 billion in 2021 to $0.27 billion in 2022 and $0.32 billion in 2023. This steady growth reflects the increasing demand for the company's digital intelligence solutions in the public safety and private sectors.

Related FAQs

Cellebrite DI Ltd.

Cellebrite DI Ltd. anticipates a robust future growth trajectory driven by accelerating law enforcement and government agency demand for digital intelligence, investigative analytics, and forensic cloud software solutions.

Police departments, federal law enforcement agencies, border security forces, and national intelligence organizations around the world utilize Cellebrite's digital forensics hardware and software solutions extensively.

Cellebrite (CLBT) does not currently maintain a traditional dividend yield structure that is widely tracked as a primary income vehicle for investors.

Wall Street research analysts covering Cellebrite DI Ltd.

Evaluating whether Cellebrite DI stock represents a solid investment opportunity depends on an investor's growth risk tolerance, software sector allocation, and market outlook.

Cellebrite DI Ltd. anticipates a strong future growth outlook driven by accelerating demand for its digital intelligence, investigative analytics, and forensic SaaS solutions among global law enforcement and government agencies.

Cellebrite DI Ltd., trading under the ticker CLBT, operates as a prominent digital intelligence software provider serving public safety, defense, and enterprise customers globally.

Equity research analysts tracking BT Group plc generally do not classify the stock as a strong buy. Market consensus leans predominantly toward a neutral or hold rating, reflecting a mix of cautious optimism and structural hesitation.

Cellebrite operates as a consistently profitable enterprise, generating positive net income, robust gross margins exceeding eighty percent, and healthy adjusted EBITDA figures supported by its transition to a high-margin subscription software model.

Software licensing and enterprise deployment costs for Cellebrite's digital intelligence and forensic investigation platform—widely utilized by law enforcement agencies, military organizations, and corporate security teams—involve substantial subscri...

The stock ticker symbol CLBT represents shares of Cellebrite DI Ltd., which is a prominent publicly traded digital intelligence and cybersecurity software enterprise listed on the Nasdaq stock exchange.

Core Laboratories Inc. provides reservoir description and production enhancement services to the oil and gas industry, exposing shareholders to specific cyclical energy sector risks.

Home appliance repair and maintenance protection plans through CenterPoint Energy's Home Service Plus (HSP) vary based on whether customers select comprehensive repair plans for individual appliances or broader home system coverage packages.

Wall Street analyst consensus for Cellebrite DI Ltd. (traded under the ticker CLBT) leans overwhelmingly toward a strong buy rating, supported by robust financial performance, accelerating annual recurring revenues, and expanding profit margins.

Celsius Holdings, Inc. commands a multi-billion-dollar corporate market valuation reflecting its strong prominence as a leading lifestyle fitness drink and functional beverage manufacturer.

Clean Harbors, like many large-scale industrial companies, has faced scenarios involving workforce reductions.

Yes, Credit One Bank, like any other financial institution, has the legal right to sue you if you default on your credit card debt.

Cellebrite DI Ltd. (CLBT) holds a consensus analyst price target averaging $21.00, with upper targets reaching up to $28.00.

Cellebrite's specialized digital intelligence software, data extraction hardware, and advanced investigative analytics platforms are not available for purchase or use by the general public.